These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9069540)

  • 21. In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae.
    Neal TJ; O'Donoghue MA; Ridgway EJ; Allen KD
    J Antimicrob Chemother; 1992 Jul; 30(1):39-46. PubMed ID: 1429335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.
    Appelbaum PC; Spangler SK; Crotty E; Jacobs MR
    J Antimicrob Chemother; 1989 Apr; 23(4):509-16. PubMed ID: 2545656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic mice.
    Zuluaga AF; Salazar BE; Agudelo M; Rodriguez CA; Vesga O
    J Biomed Sci; 2015 Mar; 22(1):24. PubMed ID: 25890037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae.
    Piroth L; Desbiolles N; Mateo-Ponce V; Martin L; Lequeu C; Charles PE; Portier H; Chavanet P
    J Antimicrob Chemother; 2001 Jan; 47(1):33-42. PubMed ID: 11152429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.
    Candiani G; Abbondi M; Borgonovi M; Romanò G; Parenti F
    J Antimicrob Chemother; 1999 Aug; 44(2):179-92. PubMed ID: 10473224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae].
    Kawada H; Kitayama A; Fukuoka T; Ishii C; Abe T; Kakuta M; Domon H; Ohya S; Utsui Y
    Jpn J Antibiot; 1999 Aug; 52(8):533-40. PubMed ID: 10587878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
    Noreddin AM; El-Khatib WF; Aolie J; Salem AH; Zhanel GG
    Int J Infect Dis; 2009 Jul; 13(4):483-7. PubMed ID: 19046911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.
    Goldstein FW; Geslin P; Acar JF
    Eur J Clin Microbiol Infect Dis; 1994 Jan; 13(1):33-4. PubMed ID: 8168558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Austrian syndrome caused by highly penicillin-resistant Streptococcus pneumoniae.
    Muñoz P; Sainz J; Rodríguez-Creixéms M; Santos J; Alcalá L; Bouza E
    Clin Infect Dis; 1999 Dec; 29(6):1591-2. PubMed ID: 10585831
    [No Abstract]   [Full Text] [Related]  

  • 34. Benzathine penicillin for unilateral lobar or segmental infiltrates presumptively caused by Streptococcus pneumoniae in children 2-12 years old.
    Camargos PA; Guimarães MD; Ferreira CS
    J Trop Pediatr; 1997 Dec; 43(6):353-60. PubMed ID: 9476458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started.
    Mufson MA; Chan G; Stanek RJ
    Am J Med Sci; 2007 Mar; 333(3):161-7. PubMed ID: 17496734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of high-dose penicillin for community-acquired pneumonia diagnosed by pneumococcal urine antigen test.
    Oka H; Ueda A; Watanuki Y; Tsukiji J; Kuroda H; Akashi S; Hirai Y; Fuyuki T; Kaneko T; Ishigatsubo Y
    J Infect Chemother; 2009 Apr; 15(2):108-12. PubMed ID: 19396521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The bactericidal activity of vancomycin and teicoplanin against Streptococcus pneumoniae.
    Felmingham D; Foxall P; O'Hare M; Grüneberg R
    Scand J Infect Dis Suppl; 1990; 72():20-5. PubMed ID: 2151062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Penicillin-resistant pneumococci and the empirical use of penicillins in the treatment of community-acquired acute pneumonia].
    Sánchez C; Armengol R; Mir I; Lite J; Garau J
    Enferm Infecc Microbiol Clin; 1992; 10(6):334-9. PubMed ID: 1391015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.